Michael Michaelides

Michael Michaelides earned his BS degree in chemistry from the SUNY at Stony Brook and his doctorate in organic chemistry from the Massachusetts Institute of Technology, under the direction of Professor William Roush, in 1988. He joined Abbott immediately after completing his graduate studies. During his 28-year tenure at Abbott and now Abbvie, Michael has carried out research in the areas of neuroscience, immunoscience and oncology. He has contributed to the invention and advancement of several clinical candidates, including adrogolide for the treatment of Parkinson’s disease and linifanib for hepatocellular carcinoma. He has over 35 issued or pending patents and 50 published articles to his name. Michael was awarded the Abbott Outstanding Researcher of the Year award in 2010. Michael is currently senior research fellow, head of Oncology Chemistry and a member of the Global Abbvie Medicinal Chemistry Leadership Team.